Pancreatic Cancer Research

ResearcherLinköping UniversityActive in the last 2 years

Bergþór Björnsson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9704-1260; OpenAlex author ID A5047322432. Sources: OpenAlex.

Their work

Papers
24 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
129
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 3 papers · 2024: 6 papers · 2025: 5 papers · 2026: 2 papers

Papers 24

  1. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  2. Futility in adenosquamous pancreatic cancer. Co-author DOI 10.1186/s12957-026-04351-1↗
  3. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  4. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  5. Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocol. Last author DOI 10.1186/s12893-025-02983-w↗
  6. PCD-CT Versus EID-CT in Imaging of Pancreatic Ductal Adenocarcinoma: A Prospective Comparative Pilot Study. Co-author DOI 10.21873/anticanres.17536↗
  7. Intratumoural expression of dihydropyrimidine dehydrogenase is an independent prognostic factor in resected pancreatic ductal adenocarcinoma treated with adjuv… Co-author DOI 10.3892/ol.2024.14845↗
  8. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  9. Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contemporary practice. Co-author DOI 10.1080/00365521.2024.2378948↗
  10. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  11. Impact of Neoadjuvant Therapy for Pancreatic Cancer: Transatlantic Trend and Postoperative Outcomes Analysis. Co-author DOI 10.1097/xcs.0000000000000971↗
  12. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  13. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Co-author DOI 10.1245/s10434-024-16021-1↗
  14. Impact of resection margins and para-aortic lymph node metastases on recurrence patterns and prognosis in resectable pancreatic cancer - a long-term population… Co-author DOI 10.1016/j.hpb.2023.08.006↗
  15. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  16. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  17. The Liver Pre-Metastatic Niche in Pancreatic Cancer: A Potential Opportunity for Intervention. First author DOI 10.3390/cancers14123028↗
  18. Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. Co-author DOI 10.1007/s00464-020-08206-y↗
  19. Preoperative Biliary Drainage Does Not Independently Reduce Survival After Pancreaticoduodenectomy Among Patients With Pancreatic Ductal Adenocarcinoma: A Nati… Last author DOI 10.1097/as9.0000000000000090↗
  20. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  21. Complete Radiologic Response of Metastatic Pancreatic Ductal Adenocarcinoma to Microwave Ablation Combined with Second-Line Palliative Chemotherapy. Last author DOI 10.1155/2020/4138215↗
  22. Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel. Co-author DOI 10.1186/s12885-020-07426-8↗
  23. 'I want to know why and need to be involved in my own care…': a qualitative interview study with liver, bile duct or pancreatic cancer patients about their exp… Co-author DOI 10.1007/s00520-018-4548-8↗
  24. Factors influencing receipt of adjuvant chemotherapy after surgery for pancreatic cancer: a two-center retrospective cohort study. First author DOI 10.1080/00365521.2016.1228118↗

Closest collaborators

The 25 strongest of 129 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nils O. Elander · 5 shared papers, 2020–2025 · strength 1.07
  2. Hakon Blomstrand · 5 shared papers, 2020–2025 · strength 1.03
  3. Bodil Andersson · 5 shared papers, 2024–2026 · strength 0.82
  4. Tobias Keck · 6 shared papers, 2021–2024 · strength 0.81
  5. Marc G. Besselink · 6 shared papers, 2021–2024 · strength 0.81
  6. Bobby Tingstedt · 4 shared papers, 2024 · strength 0.64
  7. Karin U. Johansen · 4 shared papers, 2021–2024 · strength 0.62
  8. Izaak Quintus Molenaar · 4 shared papers, 2023–2024 · strength 0.55
  9. Poya Ghorbani · 3 shared papers, 2024–2025 · strength 0.51
  10. Bas Groot Koerkamp · 4 shared papers, 2021–2024 · strength 0.50
  11. Simone Augustinus · 3 shared papers, 2024 · strength 0.48
  12. Ulrich Friedrich Wellner · 3 shared papers, 2024 · strength 0.48
  13. Henry Anthony Pitt · 3 shared papers, 2024 · strength 0.48
  14. Svein Olav Bratlie · 3 shared papers, 2021–2024 · strength 0.43
  15. Daniel Öhlund · 2 shared papers, 2025 · strength 0.43
  16. Alessandro Zerbi · 3 shared papers, 2023–2026 · strength 0.43
  17. Christopher Månsson · 2 shared papers, 2024–2025 · strength 0.36
  18. Asif Halimi · 2 shared papers, 2024–2025 · strength 0.36
  19. Ernesto Sparrelid · 2 shared papers, 2024–2025 · strength 0.36
  20. Kristina Hasselgren · 2 shared papers, 2021–2025 · strength 0.34
  21. Jakob Kirkegård · 2 shared papers, 2024–2026 · strength 0.34
  22. Riccardo Casadei · 3 shared papers, 2021–2024 · strength 0.33
  23. Andrea Pietrabissa · 3 shared papers, 2021–2024 · strength 0.33
  24. Safi Dokmak · 3 shared papers, 2021–2024 · strength 0.33
  25. Thilo Hackert · 3 shared papers, 2021–2024 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.